H. Lundbeck A/S

CPSE:HLUN B Stock Report

Market Cap: DKK 38.0b

H. Lundbeck Valuation

Is HLUN B undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of HLUN B when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
DKK 187.76
Fair Value
78.8% undervalued intrinsic discount
11
Number of Analysts

Below Fair Value: HLUN B (DKK39.74) is trading below our estimate of fair value (DKK187.76)

Significantly Below Fair Value: HLUN B is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for HLUN B?

Key metric: As HLUN B is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for HLUN B. This is calculated by dividing HLUN B's market cap by their current earnings.
What is HLUN B's PE Ratio?
PE Ratio12.5x
EarningsDKK 3.14b
Market CapDKK 38.04b

Price to Earnings Ratio vs Peers

How does HLUN B's PE Ratio compare to its peers?

The above table shows the PE ratio for HLUN B vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average36.3x
ALK B ALK-Abelló
42.9x15.7%DKK 35.0b
NOVO B Novo Nordisk
27.7x12.9%DKK 2.8t
GMAB Genmab
12.8x13.7%DKK 100.6b
CHEMM ChemoMetec
61.7x17.0%DKK 10.4b
HLUN B H. Lundbeck
12.5x6.5%DKK 38.0b

Price-To-Earnings vs Peers: HLUN B is good value based on its Price-To-Earnings Ratio (12.5x) compared to the peer average (36.3x).

Price to Earnings Ratio vs Industry

How does HLUN B's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
HLUN B 12.5xIndustry Avg. 22.7xNo. of Companies10PE01632486480+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: HLUN B is good value based on its Price-To-Earnings Ratio (12.5x) compared to the European Pharmaceuticals industry average (22.7x).

Price to Earnings Ratio vs Fair Ratio

What is HLUN B's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

HLUN B PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio12.5x
Fair PE Ratio21.2x

Price-To-Earnings vs Fair Ratio: HLUN B is good value based on its Price-To-Earnings Ratio (12.5x) compared to the estimated Fair Price-To-Earnings Ratio (21.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst HLUN B forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentDKK 39.74
DKK 51.68
+30.0%
16.9%DKK 71.00DKK 42.50n/a11
Feb ’26DKK 44.08
DKK 51.95
+17.9%
16.4%DKK 71.00DKK 42.50n/a11
Jan ’26DKK 41.32
DKK 50.15
+21.4%
14.8%DKK 69.00DKK 42.50n/a10
Dec ’25DKK 44.00
DKK 50.14
+13.9%
14.0%DKK 69.00DKK 42.50n/a11
Nov ’25DKK 45.18
DKK 48.95
+8.4%
9.2%DKK 57.00DKK 42.50n/a11
Oct ’25DKK 43.08
DKK 46.29
+7.5%
12.5%DKK 57.00DKK 35.00n/a12
Sep ’25DKK 47.92
DKK 45.54
-5.0%
12.0%DKK 57.00DKK 35.00n/a12
Aug ’25DKK 43.52
DKK 40.88
-6.1%
12.5%DKK 55.00DKK 35.00n/a12
Jul ’25DKK 38.60
DKK 39.96
+3.5%
10.9%DKK 51.00DKK 35.00n/a12
Jun ’25DKK 37.74
DKK 39.96
+5.9%
10.9%DKK 51.00DKK 35.00n/a12
May ’25DKK 34.04
DKK 38.71
+13.7%
12.3%DKK 50.00DKK 33.00n/a12
Apr ’25DKK 33.22
DKK 38.79
+16.8%
12.2%DKK 50.00DKK 33.00n/a12
Mar ’25DKK 33.06
DKK 38.35
+16.0%
12.5%DKK 50.00DKK 33.00n/a13
Feb ’25DKK 34.00
DKK 38.27
+12.6%
11.0%DKK 48.00DKK 33.00DKK 44.0813
Jan ’25DKK 32.76
DKK 38.58
+17.8%
10.4%DKK 48.00DKK 33.00DKK 41.3213
Dec ’24DKK 33.06
DKK 38.79
+17.3%
10.8%DKK 48.00DKK 32.00DKK 44.0012
Nov ’24DKK 37.16
DKK 39.05
+5.1%
11.1%DKK 47.00DKK 32.00DKK 45.1811
Oct ’24DKK 38.10
DKK 37.77
-0.9%
11.0%DKK 47.00DKK 32.00DKK 43.0811
Sep ’24DKK 35.20
DKK 37.38
+6.2%
12.0%DKK 47.00DKK 30.00DKK 47.9212
Aug ’24DKK 33.78
DKK 37.13
+9.9%
10.8%DKK 44.00DKK 30.00DKK 43.5212
Jul ’24DKK 32.44
DKK 36.88
+13.7%
12.5%DKK 44.00DKK 30.00DKK 38.6012
Jun ’24DKK 36.84
DKK 36.88
+0.1%
12.5%DKK 44.00DKK 30.00DKK 37.7412
May ’24DKK 35.70
DKK 34.63
-3.0%
15.6%DKK 44.00DKK 30.00DKK 34.0412
Apr ’24DKK 31.78
DKK 33.71
+6.1%
14.3%DKK 42.50DKK 27.00DKK 33.2212
Mar ’24DKK 29.77
DKK 33.42
+12.3%
14.2%DKK 42.50DKK 27.00DKK 33.0613
Feb ’24DKK 25.38
DKK 33.19
+30.8%
15.2%DKK 43.00DKK 27.00DKK 34.0013
Analyst Price Target
Consensus Narrative from 11 Analysts
DKK 51.68
Fair Value
23.1% undervalued intrinsic discount
11
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/21 22:45
End of Day Share Price 2025/02/21 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

H. Lundbeck A/S is covered by 42 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullABG Sundal Collier
Peter AnkersenABG Sundal Collier
Kamla SinghAlphaValue